DV
Dividend Vision

BCTX — Briacell Therapeutics Corp

Briacell Therapeutics Corp (BCTX)

Its deepest 1-year drawdown was 80.1%.

BCTX is an equity stock that focuses on Briacell Therapeutics Corp, a biotechnology company. The fund does not currently provide distributions or dividend yields, making it unsuitable for income-focused investors. This holding appeals primarily to growth-oriented investors seeking exposure to the biotechnology sector rather than those prioritizing regular income.

BCTX key facts

Asset type
Stock
Asset class
Equity
Inception date
04/16/2012
Last close
$3.44
Market cap
$32,450,206
Average volume
40500.0
Payment date
01/02/2020
Beta
1.538
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.84